{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:43:38Z","timestamp":1793947418983,"version":"4.8.0"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1038\/s41579-023-00865-7","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T12:03:17Z","timestamp":1678363397000},"page":"431-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":383,"title":["Pathogenesis, epidemiology and control of Group A Streptococcus infection"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-2992","authenticated-orcid":false,"given":"Stephan","family":"Brouwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rivera-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-6406","authenticated-orcid":false,"given":"Bodie F.","family":"Curren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-1923","authenticated-orcid":false,"given":"Nichaela","family":"Harbison-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5085-7163","authenticated-orcid":false,"given":"David M. P.","family":"De Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus G.","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-5179","authenticated-orcid":false,"given":"Mark R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-2769","authenticated-orcid":false,"given":"Mark J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"865_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.00101-13","volume":"27","author":"MJ Walker","year":"2014","unstructured":"Walker, M. J. et al. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin. Microbiol. Rev. 27, 264\u2013301 (2014).","journal-title":"Clin. Microbiol. Rev."},{"key":"865_CR2","doi-asserted-by":"publisher","first-page":"E222","DOI":"10.1111\/1469-0691.12134","volume":"19","author":"DJ McMillan","year":"2013","unstructured":"McMillan, D. J. et al. Updated model of Group A Streptococcus M proteins based on a comprehensive worldwide study. Clin. Microbiol. Infect. 19, E222\u2013E229 (2013).","journal-title":"Clin. Microbiol. Infect."},{"key":"865_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1473-3099(09)70178-1","volume":"9","author":"AC Steer","year":"2009","unstructured":"Steer, A. C., Law, I., Matatolu, L., Beall, B. W. & Carapetis, J. R. Global emm type distribution of Group A streptococci: systematic review and implications for vaccine development. Lancet Infect. Dis. 9, 611\u2013616 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S1473-3099(19)30446-3","volume":"19","author":"NN Lynskey","year":"2019","unstructured":"Lynskey, N. N. et al. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect. Dis. 19, 1209\u20131218 (2019). This paper reports a dominant new emm1 GAS lineage (M1UK) that is characterized by increased SpeA production, which may be contributing to the upsurge of scarlet fever and invasive infections in England.","journal-title":"Lancet Infect. Dis."},{"key":"865_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/infdis\/jis362","volume":"206","author":"H Tse","year":"2012","unstructured":"Tse, H. et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J. Infect. Dis. 206, 341\u2013351 (2012).","journal-title":"J. Infect. Dis."},{"key":"865_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ng.3147","volume":"47","author":"MR Davies","year":"2015","unstructured":"Davies, M. R. et al. Emergence of scarlet fever Streptococcus pyogenes emm12 clones in Hong Kong is associated with toxin acquisition and multidrug resistance. Nat. Genet. 47, 84\u201387 (2015).","journal-title":"Nat. Genet."},{"key":"865_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3201\/eid2206.151726","volume":"22","author":"CE Turner","year":"2016","unstructured":"Turner, C. E. et al. Scarlet fever upsurge in England and molecular-genetic analysis in North-West London, 2014. Emerg. Infect. Dis. 22, 1075\u20131078 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-021-04384-4","volume":"602","author":"W Deng","year":"2022","unstructured":"Deng, W. et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature 602, 496\u2013502 (2022). This paper reports demonstrating that SpeB triggers keratinocyte pyroptosis by cleaving GSDMA, providing a mechanism for inflammatory response stimulation at the epithelial cell layer.","journal-title":"Nature"},{"key":"865_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41586-022-04717-x","volume":"605","author":"DL LaRock","year":"2022","unstructured":"LaRock, D. L. et al. Group A Streptococcus induces GSDMA-dependent pyroptosis in keratinocytes. Nature 605, 527\u2013531 (2022). This paper demonstrates the roles of SpeB in caspase 1-independent activation of GSDMA in skin cells.","journal-title":"Nature"},{"key":"865_CR10","doi-asserted-by":"publisher","first-page":"25923","DOI":"10.1073\/pnas.1910883116","volume":"116","author":"J Emg\u00e5rd","year":"2019","unstructured":"Emg\u00e5rd, J. et al. MAIT cells are major contributors to the cytokine response in Group A streptococcal toxic shock syndrome. Proc. Natl Acad. Sci. USA 116, 25923\u201325931 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR11","doi-asserted-by":"publisher","first-page":"e01993-19","DOI":"10.1128\/JCM.01993-19","volume":"58","author":"JM Musser","year":"2020","unstructured":"Musser, J. M. et al. Reduced in vitro susceptibility of Streptococcus pyogenes to \u03b2-lactam antibiotics associated with mutations in the pbp2x gene is geographically widespread. J. Clin. Microbiol. 58, e01993-19 (2020).","journal-title":"J. Clin. Microbiol."},{"key":"865_CR12","doi-asserted-by":"publisher","first-page":"e00090-20","DOI":"10.1128\/mSphere.00090-20","volume":"5","author":"A Hayes","year":"2020","unstructured":"Hayes, A., Lacey, J. A., Morris, J. M., Davies, M. R. & Tong, S. Y. C. Restricted sequence variation in Streptococcus pyogenes penicillin binding proteins. mSphere 5, e00090-20 (2020).","journal-title":"mSphere"},{"key":"865_CR13","doi-asserted-by":"publisher","first-page":"e01422-17","DOI":"10.1128\/mBio.01422-17","volume":"8","author":"S Chochua","year":"2017","unstructured":"Chochua, S. et al. Population and whole genome sequence based characterization of invasive Group A streptococci recovered in the United States during 2015. mBio 8, e01422-17 (2017). This work presents a detailed large-scale population-based genomic characterization of invasive GAS isolates in the United States.","journal-title":"mBio"},{"key":"865_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/cid\/ciz1000","volume":"71","author":"KS Vannice","year":"2020","unstructured":"Vannice, K. S. et al. Streptococcus pyogenes pbp2x mutation confers reduced susceptibility to \u03b2-lactam antibiotics. Clin. Infect. Dis. 71, 201\u2013204 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00802-22","volume":"66","author":"S Chochua","year":"2022","unstructured":"Chochua, S. et al. Invasive Group A streptococcal penicillin binding protein 2x variants associated with reduced susceptibility to \u03b2-lactam antibiotics in the United States, 2015\u20132021. Antimicrob. Agents Chemother. 66, e0080222 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/cid\/ciy1143","volume":"69","author":"GR Vekemans","year":"2019","unstructured":"Vekemans, G. R. & Kim The path to Group A Streptococcus vaccines: WHO research and development technology roadmap and preferred product characteristics. Clin. Infect. Dis. 69, 877\u2013883 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41588-019-0417-8","volume":"51","author":"MR Davies","year":"2019","unstructured":"Davies, M. R. et al. Atlas of Group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat. Genet. 51, 1035\u20131043 (2019). This study uses global GAS genomic data sets to develop a platform for genomics-informed vaccine design.","journal-title":"Nat. Genet."},{"key":"865_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QCO.0000000000000644","volume":"33","author":"JB Dale","year":"2020","unstructured":"Dale, J. B. & Walker, M. J. Update on Group A streptococcal vaccine development. Curr. Opin. Infect. Dis. 33, 244\u2013250 (2020).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"865_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00693-19","volume":"10","author":"T Rivera-Hernandez","year":"2019","unstructured":"Rivera-Hernandez, T. et al. An experimental Group A Streptococcus vaccine that reduces pharyngitis and tonsillitis in a nonhuman primate model. mBio 10, e00693-19 (2019).","journal-title":"mBio"},{"key":"865_CR20","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2666-5247(20)30240-8","volume":"2","author":"J Osowicki","year":"2021","unstructured":"Osowicki, J. et al. A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. Lancet Microbe 2, e291\u2013e299 (2021). This landmark paper reports the first controlled GAS human infection model of pharyngitis.","journal-title":"Lancet Microbe"},{"key":"865_CR21","doi-asserted-by":"crossref","unstructured":"Hand, R. M., Snelling, T. L. & Carapetis, J. R. Group A Streptococcus. in Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases (eds Ryan, E. T., Hill, D. R., Solomon, T., Aronson, N. E. & Endy, T. P.) 429\u2013438 (Elsevier, 2020).","DOI":"10.1016\/B978-0-323-55512-8.00040-5"},{"key":"865_CR22","doi-asserted-by":"publisher","first-page":"101458","DOI":"10.1016\/j.eclinm.2022.101458","volume":"48","author":"KM Miller","year":"2022","unstructured":"Miller, K. M. et al. The global burden of sore throat and Group A Streptococcus pharyngitis: a systematic review and meta-analysis. EClinicalMedicine 48, 101458 (2022).","journal-title":"EClinicalMedicine"},{"key":"865_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijid.2020.11.193","volume":"103","author":"JW Cannon","year":"2021","unstructured":"Cannon, J. W. et al. The economic and health burdens of diseases caused by Group A Streptococcus in New Zealand. Int. J. Infect. Dis. 103, 176\u2013181 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"865_CR24","doi-asserted-by":"publisher","first-page":"e1388","DOI":"10.1016\/S2214-109X(19)30360-2","volume":"7","author":"P Ordunez","year":"2019","unstructured":"Ordunez, P. et al. Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990\u20132017: a population-based study. Lancet Glob. Health 7, e1388\u2013e1397 (2019).","journal-title":"Lancet Glob. Health"},{"key":"865_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/eurjpc\/zwac044","volume":"29","author":"M Lv","year":"2022","unstructured":"Lv, M. et al. Global burden of rheumatic heart disease and its association with socioeconomic development status, 1990\u20132019. Eur. J. Prev. Cardiol. 29, 1425\u20131434 (2022).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"865_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020992","volume":"10","author":"SR de Loizaga","year":"2021","unstructured":"de Loizaga, S. R. et al. Rheumatic heart disease in the United States: forgotten but not gone: results of a 10 year multicenter review. J. Am. Heart Assoc. 10, e020992 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"865_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-007038","volume":"6","author":"J Oliver","year":"2021","unstructured":"Oliver, J. et al. Preceding Group A Streptococcus skin and throat infections are individually associated with acute rheumatic fever: evidence from New Zealand. BMJ Glob. Health 6, e007038 (2021).","journal-title":"BMJ Glob. Health"},{"key":"865_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057296","volume":"12","author":"DD Barth","year":"2022","unstructured":"Barth, D. D. et al. Missing piece study protocol: prospective surveillance to determine the epidemiology of Group A streptococcal pharyngitis and impetigo in remote Western Australia. BMJ Open 12, e057296 (2022).","journal-title":"BMJ Open"},{"key":"865_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3201\/eid2304.160773","volume":"23","author":"DW Park","year":"2017","unstructured":"Park, D. W. et al. Incidence and characteristics of scarlet fever, South Korea, 2008\u20132015. Emerg. Infect. Dis. 23, 658\u2013661 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR30","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1473-3099(18)30464-X","volume":"18","author":"CF Yung","year":"2018","unstructured":"Yung, C. F. & Thoon, K. C. A 12 year outbreak of scarlet fever in Singapore. Lancet Infect. Dis. 18, 942 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S1473-3099(17)30693-X","volume":"18","author":"T Lamagni","year":"2018","unstructured":"Lamagni, T. et al. Resurgence of scarlet fever in England, 2014\u201316: a population-based surveillance study. Lancet Infect. Dis. 18, 180\u2013187 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR32","doi-asserted-by":"publisher","first-page":"000274","DOI":"10.1099\/acmi.0.000274","volume":"3","author":"MB Cubria","year":"2021","unstructured":"Cubria, M. B., Delgado, J., Shah, B. J., Sanson, M. A. & Flores, A. R. Identification of epidemic scarlet fever Group A Streptococcus strains in the paediatric population of Houston, TX, USA. Access. Microbiol. 3, 000274 (2021).","journal-title":"Access. Microbiol."},{"key":"865_CR33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/cid\/ciz099","volume":"69","author":"MJ Walker","year":"2019","unstructured":"Walker, M. J. et al. Detection of epidemic scarlet fever Group A Streptococcus in Australia. Clin. Infect. Dis. 69, 1232\u20131234 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3201\/eid2503.181518","volume":"25","author":"V Watts","year":"2019","unstructured":"Watts, V. et al. Increased risk for invasive Group A Streptococcus disease for household contacts of scarlet fever cases, England, 2011\u20132016. Emerg. Infect. Dis. 25, 529\u2013537 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3201\/eid2801.210733","volume":"28","author":"M Ron","year":"2022","unstructured":"Ron, M. et al. Invasive multidrug-resistant emm93.0 Streptococcus pyogenes strain harboring a novel genomic island, Israel, 2017\u20132019. Emerg. Infect. Dis. 28, 118\u2013126 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3201\/eid2702.201945","volume":"27","author":"GJ Tyrrell","year":"2021","unstructured":"Tyrrell, G. J., Bell, C., Bill, L. & Fathima, S. Increasing incidence of invasive Group A Streptococcus disease in first nations population, Alberta, Canada, 2003\u20132017. Emerg. Infect. Dis. 27, 443\u2013451 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR37","doi-asserted-by":"publisher","first-page":"e3718","DOI":"10.1093\/cid\/ciaa787","volume":"73","author":"SJ Valenciano","year":"2021","unstructured":"Valenciano, S. J. et al. Invasive Group A streptococcal infections among people who inject drugs and people experiencing homelessness in the United States, 2010\u20132017. Clin. Infect. Dis. 73, e3718\u2013e3726 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR38","doi-asserted-by":"publisher","first-page":"4689","DOI":"10.1073\/pnas.78.8.4689","volume":"78","author":"GN Phillips Jr","year":"1981","unstructured":"Phillips, G. N. Jr, Flicker, P. F., Cohen, C., Manjula, B. N. & Fischetti, V. A. Streptococcal M protein: \u03b1-helical coiled-coil structure and arrangement on the cell surface. Proc. Natl Acad. Sci. USA 78, 4689\u20134693 (1981).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR39","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1086\/379050","volume":"188","author":"Z Li","year":"2003","unstructured":"Li, Z. et al. Array of M protein gene subtypes in 1064 recent invasive Group A Streptococcus isolates recovered from the active bacterial core surveillance. J. Infect. Dis. 188, 1587\u20131592 (2003).","journal-title":"J. Infect. Dis."},{"key":"865_CR40","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41564-017-0005-6","volume":"2","author":"JA Valderrama","year":"2017","unstructured":"Valderrama, J. A. et al. Group A streptococcal M protein activates the NLRP3 inflammasome. Nat. Microbiol. 2, 1425\u20131434 (2017). This comprehensive report demonstrates that M1 protein triggers caspase 1-dependent NLRP3 inflammasome activation, leading to pyroptotic macrophage cell death.","journal-title":"Nat. Microbiol."},{"key":"865_CR41","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/imcb.12499","volume":"99","author":"J Richter","year":"2021","unstructured":"Richter, J. et al. Streptolysins are the primary inflammasome activators in macrophages during Streptococcus pyogenes infection. Immunol. Cell Biol. 99, 1040\u20131052 (2021).","journal-title":"Immunol. Cell Biol."},{"key":"865_CR42","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1073\/pnas.92.7.2489","volume":"92","author":"N Okada","year":"1995","unstructured":"Okada, N., Liszewski, M. K., Atkinson, J. P. & Caparon, M. Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the Group A Streptococcus. Proc. Natl Acad. Sci. USA 92, 2489\u20132493 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR43","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1128\/IAI.69.12.7402-7412.2001","volume":"69","author":"PA Ryan","year":"2001","unstructured":"Ryan, P. A., Pancholi, V. & Fischetti, V. A. Group A streptococci bind to mucin and human pharyngeal cells through sialic acid-containing receptors. Infect. Immun. 69, 7402\u20137412 (2001).","journal-title":"Infect. Immun."},{"key":"865_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02237-16","volume":"8","author":"DM De Oliveira","year":"2017","unstructured":"De Oliveira, D. M. et al. Blood group antigen recognition via the Group A streptococcal M protein mediates host colonization. mBio 8, e02237-16 (2017).","journal-title":"mBio"},{"key":"865_CR45","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1016\/j.molimm.2007.03.012","volume":"44","author":"MJ Feito","year":"2007","unstructured":"Feito, M. J. et al. Membrane cofactor protein (MCP, CD46) binding to clinical isolates of Streptococcus pyogenes: binding to M type 18 strains is independent of Emm or Enn proteins. Mol. Immunol. 44, 3571\u20133579 (2007).","journal-title":"Mol. Immunol."},{"key":"865_CR46","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/0092-8674(90)90694-A","volume":"61","author":"A Aruffo","year":"1990","unstructured":"Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303\u20131313 (1990).","journal-title":"Cell"},{"key":"865_CR47","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/414648a","volume":"414","author":"C Cywes","year":"2001","unstructured":"Cywes, C. & Wessels, M. R. Group A Streptococcus tissue invasion by CD44-mediated cell signalling. Nature 414, 648\u2013652 (2001).","journal-title":"Nature"},{"key":"865_CR48","doi-asserted-by":"publisher","unstructured":"Wessels, M. R. Capsular polysaccharide of Group A Streptococcus. Microbiol. Spectr. 7, https:\/\/doi.org\/10.1128\/microbiolspec.GPP3-0050-2018\u00a0(2019).","DOI":"10.1128\/microbiolspec.GPP3-0050-2018"},{"key":"865_CR49","doi-asserted-by":"publisher","first-page":"e00413","DOI":"10.1128\/mBio.00413-12","volume":"3","author":"AR Flores","year":"2012","unstructured":"Flores, A. R., Jewell, B. E., Fittipaldi, N., Beres, S. B. & Musser, J. M. Human disease isolates of serotype M4 and M22 Group A Streptococcus lack genes required for hyaluronic acid capsule biosynthesis. mBio 3, e00413\u201312 (2012).","journal-title":"mBio"},{"key":"865_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00622-15","volume":"6","author":"CE Turner","year":"2015","unstructured":"Turner, C. E. et al. Emergence of a new highly successful acapsular Group A Streptococcus clade of genotype emm89 in the United Kingdom. mBio 6, e00622 (2015).","journal-title":"mBio"},{"key":"865_CR51","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jpids\/piy053","volume":"8","author":"AR Flores","year":"2019","unstructured":"Flores, A. R., Chase McNeil, J., Shah, B., Van Beneden, C. & Shelburne, S. A. Capsule-negative emm types are an increasing cause of pediatric Group A streptococcal infections at a large pediatric hospital in Texas. J. Pediatr. Infect. Dis. Soc. 8, 244\u2013250 (2019).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"865_CR52","doi-asserted-by":"publisher","first-page":"e02521-19","DOI":"10.1128\/mBio.02521-19","volume":"10","author":"CE Turner","year":"2019","unstructured":"Turner, C. E. et al. The emergence of successful Streptococcus pyogenes lineages through convergent pathways of capsule loss and recombination directing high toxin expression. mBio 10, e02521-19 (2019).","journal-title":"mBio"},{"key":"865_CR53","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.celrep.2019.11.001","volume":"29","author":"IH Wierzbicki","year":"2019","unstructured":"Wierzbicki, I. H. et al. Group A streptococcal S protein utilizes red blood cells as immune camouflage and is a critical determinant for immune evasion. Cell Rep. 29, 2979\u20132989.e15 (2019). This study utilizes biomimetic virulomics to show that GAS S protein captures lysed red blood cell membranes to cloak the bacterial cell surface, which allows bacteria to evade host immunity.","journal-title":"Cell Rep."},{"key":"865_CR54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000181144","volume":"1","author":"J Potempa","year":"2009","unstructured":"Potempa, J. & Pike, R. N. Corruption of innate immunity by bacterial proteases. J. Innate Immun. 1, 70\u201387 (2009).","journal-title":"J. Innate Immun."},{"key":"865_CR55","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1086\/432485","volume":"192","author":"RJ Edwards","year":"2005","unstructured":"Edwards, R. J. et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis. 192, 783\u2013790 (2005).","journal-title":"J. Infect. Dis."},{"key":"865_CR56","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1128\/iai.60.12.5219-5223.1992","volume":"60","author":"PP Cleary","year":"1992","unstructured":"Cleary, P. P., Prahbu, U., Dale, J. B., Wexler, D. E. & Handley, J. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect. Immun. 60, 5219\u20135223 (1992).","journal-title":"Infect. Immun."},{"key":"865_CR57","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1099\/mic.0.000612","volume":"164","author":"A Remmington","year":"2018","unstructured":"Remmington, A. & Turner, C. E. The DNases of pathogenic Lancefield streptococci. Microbiology 164, 242\u2013250 (2018).","journal-title":"Microbiology"},{"key":"865_CR58","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1073\/pnas.0406641102","volume":"102","author":"P Sumby","year":"2005","unstructured":"Sumby, P. et al. Extracellular deoxyribonuclease made by Group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc. Natl Acad. Sci. USA 102, 1679\u20131684 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR59","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1099\/mic.0.031955-0","volume":"156","author":"T Hasegawa","year":"2010","unstructured":"Hasegawa, T. et al. Characterization of a virulence-associated and cell-wall-located DNase of Streptococcus pyogenes. Microbiology 156, 184\u2013190 (2010).","journal-title":"Microbiology"},{"key":"865_CR60","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cub.2005.12.039","volume":"16","author":"JT Buchanan","year":"2006","unstructured":"Buchanan, J. T. et al. DNase expression allows the pathogen Group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16, 396\u2013400 (2006).","journal-title":"Curr. Biol."},{"key":"865_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18700-5","volume":"11","author":"S Brouwer","year":"2020","unstructured":"Brouwer, S. et al. Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes. Nat. Commun. 11, 5018 (2020). This paper reports the thiol-activated bacterial superantigen, showcasing the relationship between prophage exotoxins and virulence phenotypes of scarlet fever-causing GAS.","journal-title":"Nat. Commun."},{"key":"865_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60306-w","volume":"10","author":"M Tanaka","year":"2020","unstructured":"Tanaka, M. et al. Group A Streptococcus establishes pharynx infection by degrading the deoxyribonucleic acid of neutrophil extracellular traps. Sci. Rep. 10, 3251 (2020).","journal-title":"Sci. Rep."},{"key":"865_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002736","volume":"8","author":"S Uchiyama","year":"2012","unstructured":"Uchiyama, S., Andreoni, F., Schuepbach, R. A., Nizet, V. & Zinkernagel, A. S. DNase Sda1 allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognition. PLoS Pathog. 8, e1002736 (2012).","journal-title":"PLoS Pathog."},{"key":"865_CR64","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1086\/377100","volume":"188","author":"J Khil","year":"2003","unstructured":"Khil, J. et al. Plasminogen enhances virulence of Group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J. Infect. Dis. 188, 497\u2013505 (2003).","journal-title":"J. Infect. Dis."},{"key":"865_CR65","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1126\/science.1101245","volume":"305","author":"H Sun","year":"2004","unstructured":"Sun, H. et al. Plasminogen is a critical host pathogenicity factor for Group A streptococcal infection. Science 305, 1283\u20131286 (2004).","journal-title":"Science"},{"key":"865_CR66","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1096\/fj.08-109348","volume":"22","author":"JD McArthur","year":"2008","unstructured":"McArthur, J. D. et al. Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activation. FASEB J. 22, 3146\u20133153 (2008).","journal-title":"FASEB J."},{"key":"865_CR67","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1159\/000448039","volume":"8","author":"R Nitzsche","year":"2016","unstructured":"Nitzsche, R., Kohler, J., Kreikemeyer, B. & Oehmcke-Hecht, S. Streptococcus pyogenes escapes killing from extracellular histones through plasminogen binding and activation by streptokinase. J. Innate Immun. 8, 589\u2013600 (2016).","journal-title":"J. Innate Immun."},{"key":"865_CR68","doi-asserted-by":"publisher","first-page":"15540","DOI":"10.1021\/bi048284d","volume":"43","author":"B Vincents","year":"2004","unstructured":"Vincents, B., von Pawel-Rammingen, U., Bjorck, L. & Abrahamson, M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry 43, 15540\u201315549 (2004).","journal-title":"Biochemistry"},{"key":"865_CR69","doi-asserted-by":"publisher","first-page":"52789","DOI":"10.1074\/jbc.M410698200","volume":"279","author":"J Agniswamy","year":"2004","unstructured":"Agniswamy, J., Lei, B., Musser, J. M. & Sun, P. D. Insight of host immune evasion mediated by two variants of Group A Streptococcus Mac protein. J. Biol. Chem. 279, 52789\u201352796 (2004).","journal-title":"J. Biol. Chem."},{"key":"865_CR70","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1084\/jem.20190293","volume":"216","author":"A Naegeli","year":"2019","unstructured":"Naegeli, A. et al. Streptococcus pyogenes evades adaptive immunity through specific IgG glycan hydrolysis. J. Exp. Med. 216, 1615\u20131629 (2019).","journal-title":"J. Exp. Med."},{"key":"865_CR71","doi-asserted-by":"publisher","first-page":"13317","DOI":"10.1074\/jbc.M113.459875","volume":"288","author":"T Sumitomo","year":"2013","unstructured":"Sumitomo, T., Nakata, M., Higashino, M., Terao, Y. & Kawabata, S. Group A streptococcal cysteine protease cleaves epithelial junctions and contributes to bacterial translocation. J. Biol. Chem. 288, 13317\u201313324 (2013).","journal-title":"J. Biol. Chem."},{"key":"865_CR72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/mpat.1993.1083","volume":"15","author":"V Kapur","year":"1993","unstructured":"Kapur, V. et al. A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb. Pathog. 15, 327\u2013346 (1993).","journal-title":"Microb. Pathog."},{"key":"865_CR73","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.1074\/jbc.M704821200","volume":"283","author":"Y Terao","year":"2008","unstructured":"Terao, Y. et al. Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J. Biol. Chem. 283, 6253\u20136260 (2008).","journal-title":"J. Biol. Chem."},{"key":"865_CR74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2958.2002.03146.x","volume":"46","author":"A Schmidtchen","year":"2002","unstructured":"Schmidtchen, A., Frick, I. M., Andersson, E., Tapper, H. & Bjorck, L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. 46, 157\u2013168 (2002).","journal-title":"Mol. Microbiol."},{"key":"865_CR75","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.chom.2013.11.003","volume":"14","author":"TC Barnett","year":"2013","unstructured":"Barnett, T. C. et al. The globally disseminated M1T1 clone of Group A Streptococcus evades autophagy for intracellular replication. Cell Host Microbe 14, 675\u2013682 (2013).","journal-title":"Cell Host Microbe"},{"key":"865_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004769","volume":"4","author":"A Egesten","year":"2009","unstructured":"Egesten, A. et al. SpeB of Streptococcus pyogenes differentially modulates antibacterial and receptor activating properties of human chemokines. PLoS ONE 4, e4769 (2009).","journal-title":"PLoS ONE"},{"key":"865_CR77","doi-asserted-by":"publisher","first-page":"7676","DOI":"10.1073\/pnas.90.16.7676","volume":"90","author":"V Kapur","year":"1993","unstructured":"Kapur, V., Majesky, M. W., Li, L. L., Black, R. A. & Musser, J. M. Cleavage of interleukin 1\u03b2 (IL-1\u03b2) precursor to produce active IL-1\u03b2 by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc. Natl Acad. Sci. USA 90, 7676\u20137680 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR78","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.celrep.2020.108515","volume":"33","author":"T Macleod","year":"2020","unstructured":"Macleod, T. et al. The proinflammatory cytokine IL-36\u03b3 is a global discriminator of harmless microbes and invasive pathogens within epithelial tissues. Cell Rep. 33, 108515 (2020). This important study demonstrates that epithelial cytokine IL-36\u03b3 is a global sensor of pathogen-derived proteases during epithelial infection.","journal-title":"Cell Rep."},{"key":"865_CR79","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1128\/IAI.68.11.6362-6369.2000","volume":"68","author":"RG Kansal","year":"2000","unstructured":"Kansal, R. G., McGeer, A., Low, D. E., Norrby-Teglund, A. & Kotb, M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive Group A streptococcal infection cases. Infect. Immun. 68, 6362\u20136369 (2000).","journal-title":"Infect. Immun."},{"key":"865_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0020005","volume":"2","author":"P Sumby","year":"2006","unstructured":"Sumby, P., Whitney, A. R., Graviss, E. A., DeLeo, F. R. & Musser, J. M. Genome-wide analysis of Group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2, e5 (2006).","journal-title":"PLoS Pathog."},{"key":"865_CR81","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/nm1612","volume":"13","author":"MJ Walker","year":"2007","unstructured":"Walker, M. J. et al. DNase Sda1 provides selection pressure for a switch to invasive Group A streptococcal infection. Nat. Med. 13, 981\u2013985 (2007). This comprehensive report details the molecular basis of natural selection of hypervirulent bacterial variants with increased risk of systemic dissemination.","journal-title":"Nat. Med."},{"key":"865_CR82","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1159\/000317640","volume":"2","author":"PG Maamary","year":"2010","unstructured":"Maamary, P. G. et al. Parameters governing invasive disease propensity of non-M1 serotype Group A streptococci. J. Innate Immun. 2, 596\u2013606 (2010).","journal-title":"J. Innate Immun."},{"key":"865_CR83","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1096\/fj.06-5804fje","volume":"20","author":"JN Cole","year":"2006","unstructured":"Cole, J. N. et al. Trigger for Group A streptococcal M1T1 invasive disease. FASEB J. 20, 1745\u20131747 (2006).","journal-title":"FASEB J."},{"key":"865_CR84","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrmicro2624","volume":"9","author":"EM Molloy","year":"2011","unstructured":"Molloy, E. M., Cotter, P. D., Hill, C., Mitchell, D. A. & Ross, R. P. Streptolysin S-like virulence factors: the continuing sagA. Nat. Rev. Microbiol. 9, 670\u2013681 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"865_CR85","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1128\/IAI.71.1.446-455.2003","volume":"71","author":"G Sierig","year":"2003","unstructured":"Sierig, G., Cywes, C., Wessels, M. R. & Ashbaugh, C. D. Cytotoxic effects of streptolysin O and streptolysin S enhance the virulence of poorly encapsulated Group A streptococci. Infect. Immun. 71, 446\u2013455 (2003).","journal-title":"Infect. Immun."},{"key":"865_CR86","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1128\/IAI.00611-15","volume":"83","author":"RA Flaherty","year":"2015","unstructured":"Flaherty, R. A., Puricelli, J. M., Higashi, D. L., Park, C. J. & Lee, S. W. Streptolysin S promotes programmed cell death and enhances inflammatory signaling in epithelial keratinocytes during Group A Streptococcus infection. Infect. Immun. 83, 4118\u20134133 (2015).","journal-title":"Infect. Immun."},{"key":"865_CR87","first-page":"581","volume":"6","author":"S Uchiyama","year":"2015","unstructured":"Uchiyama, S. et al. Streptolysin O rapidly impairs neutrophil oxidative burst and antibacterial responses to Group A. Streptococcus. Front. Immunol. 6, 581 (2015).","journal-title":"Streptococcus. Front. Immunol."},{"key":"865_CR88","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1462-5822.2008.01245.x","volume":"11","author":"O Goldmann","year":"2009","unstructured":"Goldmann, O., Sastalla, I., Wos-Oxley, M., Rohde, M. & Medina, E. Streptococcus pyogenes induces oncosis in macrophages through the activation of an inflammatory programmed cell death pathway. Cell. Microbiol. 11, 138\u2013155 (2009).","journal-title":"Cell. Microbiol."},{"key":"865_CR89","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.cell.2018.04.006","volume":"173","author":"FA Pinho-Ribeiro","year":"2018","unstructured":"Pinho-Ribeiro, F. A. et al. Blocking neuronal signaling to immune cells treats streptococcal invasive infection. Cell 173, 1083\u20131097 e22 (2018). This work demonstrates how GAS exploits neuro-immunological signalling to cause invasive infection.","journal-title":"Cell"},{"key":"865_CR90","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bbaexp.2004.10.011","volume":"1681","author":"H Kimoto","year":"2005","unstructured":"Kimoto, H., Fujii, Y., Yokota, Y. & Taketo, A. Molecular characterization of NADase\u2013streptolysin O operon of hemolytic streptococci. Biochim. Biophys. Acta 1681, 134\u2013149 (2005).","journal-title":"Biochim. Biophys. Acta"},{"key":"865_CR91","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1074\/jbc.M511674200","volume":"281","author":"A Michos","year":"2006","unstructured":"Michos, A. et al. Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the Group A streptococcal toxin, NAD-glycohydrolase. J. Biol. Chem. 281, 8216\u20138223 (2006).","journal-title":"J. Biol. Chem."},{"key":"865_CR92","doi-asserted-by":"publisher","first-page":"e01382-17","DOI":"10.1128\/mBio.01382-17","volume":"8","author":"JJ Velarde","year":"2017","unstructured":"Velarde, J. J., O\u2019Seaghdha, M., Baddal, B., Bastiat-Sempe, B. & Wessels, M. R. Binding of NAD+-glycohydrolase to streptolysin O stabilizes both toxins and promotes virulence of Group A Streptococcus. mBio 8, e01382-17 (2017).","journal-title":"mBio"},{"key":"865_CR93","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00366-21","volume":"204","author":"JJ Velarde","year":"2022","unstructured":"Velarde, J. J. et al. Structure of the Streptococcus pyogenes NAD+ glycohydrolase translocation domain and its essential role in toxin binding to oropharyngeal keratinocytes. J. Bacteriol. 204, e0036621 (2022).","journal-title":"J. Bacteriol."},{"key":"865_CR94","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/embor.2010.37","volume":"11","author":"N Magassa","year":"2010","unstructured":"Magassa, N., Chandrasekaran, S. & Caparon, M. G. Streptococcus pyogenes cytolysin-mediated translocation does not require pore formation by streptolysin O. EMBO Rep. 11, 400\u2013405 (2010).","journal-title":"EMBO Rep."},{"key":"865_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003394","volume":"9","author":"M O\u2019Seaghdha","year":"2013","unstructured":"O\u2019Seaghdha, M. & Wessels, M. R. Streptolysin O and its co-toxin NAD-glycohydrolase protect Group A Streptococcus from xenophagic killing. PLoS Pathog. 9, e1003394 (2013).","journal-title":"PLoS Pathog."},{"key":"865_CR96","doi-asserted-by":"publisher","first-page":"e01690-14","DOI":"10.1128\/mBio.01690-14","volume":"5","author":"B Bastiat-Sempe","year":"2014","unstructured":"Bastiat-Sempe, B., Love, J. F., Lomayesva, N. & Wessels, M. R. Streptolysin O and NAD-glycohydrolase prevent phagolysosome acidification and promote Group A Streptococcus survival in macrophages. mBio 5, e01690-14 (2014).","journal-title":"mBio"},{"key":"865_CR97","doi-asserted-by":"publisher","first-page":"e01974-20","DOI":"10.1128\/mBio.01974-20","volume":"12","author":"T Nozawa","year":"2021","unstructured":"Nozawa, T. et al. Intracellular Group A Streptococcus induces golgi fragmentation to impair host defenses through streptolysin O and NAD-glycohydrolase. mBio 12, e01974-20 (2021).","journal-title":"mBio"},{"key":"865_CR98","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ajpath.2016.11.003","volume":"187","author":"L Zhu","year":"2017","unstructured":"Zhu, L. et al. Contribution of secreted NADase and streptolysin O to the pathogenesis of epidemic serotype M1 Streptococcus pyogenes infections. Am. J. Pathol. 187, 605\u2013613 (2017).","journal-title":"Am. J. Pathol."},{"key":"865_CR99","doi-asserted-by":"publisher","first-page":"E1768","DOI":"10.1073\/pnas.1403138111","volume":"111","author":"W Nasser","year":"2014","unstructured":"Nasser, W. et al. Evolutionary pathway to increased virulence and epidemic Group A Streptococcus disease derived from 3,615 genome sequences. Proc. Natl Acad. Sci. USA 111, E1768\u2013E1776 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"865_CR100","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1172\/JCI82478","volume":"125","author":"L Zhu","year":"2015","unstructured":"Zhu, L. et al. A molecular trigger for intercontinental epidemics of Group A Streptococcus. J. Clin. Invest. 125, 3545\u20133559 (2015).","journal-title":"J. Clin. Invest."},{"key":"865_CR101","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev.micro.55.1.77","volume":"55","author":"JK McCormick","year":"2001","unstructured":"McCormick, J. K., Yarwood, J. M. & Schlievert, P. M. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55, 77\u2013104 (2001).","journal-title":"Annu. Rev. Microbiol."},{"key":"865_CR102","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jinf.2019.02.005","volume":"78","author":"M Reglinski","year":"2019","unstructured":"Reglinski, M., Sriskandan, S. & Turner, C. E. Identification of two new core chromosome-encoded superantigens in Streptococcus pyogenes; speQ and speR. J. Infect. 78, 358\u2013363 (2019).","journal-title":"J. Infect."},{"key":"865_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004155","volume":"10","author":"KJ Kasper","year":"2014","unstructured":"Kasper, K. J. et al. Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC class II-dependent manner. PLoS Pathog. 10, e1004155 (2014). This paper presents clear evidence that streptococcal superantigens are critical for the establishment of acute infection of the upper respiratory tract by GAS.","journal-title":"PLoS Pathog."},{"key":"865_CR104","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1086\/322018","volume":"184","author":"S Sriskandan","year":"2001","unstructured":"Sriskandan, S. et al. Enhanced susceptibility to superantigen-associated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice. J. Infect. Dis. 184, 166\u2013173 (2001).","journal-title":"J. Infect. Dis."},{"key":"865_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28335-3","volume":"13","author":"J Anderson","year":"2022","unstructured":"Anderson, J. et al. Immune signature of acute pharyngitis in a Streptococcus pyogenes human challenge trial. Nat. Commun. 13, 769 (2022).","journal-title":"Nat. Commun."},{"key":"865_CR106","doi-asserted-by":"publisher","first-page":"eaau3776","DOI":"10.1126\/scitranslmed.aau3776","volume":"11","author":"JM Dan","year":"2019","unstructured":"Dan, J. M. et al. Recurrent Group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells. Sci. Transl. Med. 11, eaau3776 (2019).","journal-title":"Sci. Transl. Med."},{"key":"865_CR107","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/ni.1890","volume":"11","author":"L Le Bourhis","year":"2010","unstructured":"Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 11, 701\u2013708 (2010). This study demonstrates that mucosal-associated invariant T lymphocytes (MAIT lymphocytes) are evolutionarily conserved innate-like T cells that sense and help fight microbial infection.","journal-title":"Nat. Immunol."},{"key":"865_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12506","volume":"7","author":"EW Meermeier","year":"2016","unstructured":"Meermeier, E. W. et al. Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens. Nat. Commun. 7, 12506 (2016).","journal-title":"Nat. Commun."},{"key":"865_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2001930","volume":"15","author":"CR Shaler","year":"2017","unstructured":"Shaler, C. R. et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol. 15, e2001930 (2017).","journal-title":"PLoS Biol."},{"key":"865_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016764","volume":"6","author":"AY Tilahun","year":"2011","unstructured":"Tilahun, A. Y., Holz, M., Wu, T.-T., David, C. S. & Rajagopalan, G. Interferon \u03b3-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome. PLoS ONE 6, e16764 (2011).","journal-title":"PLoS ONE"},{"key":"865_CR111","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijcard.2021.02.020","volume":"333","author":"M Ozkaya","year":"2021","unstructured":"Ozkaya, M. et al. The number and activity of CD3 TCR V\u03b17.2 CD161 cells are increased in children with acute rheumatic fever. Int. J. Cardiol. 333, 174\u2013183 (2021).","journal-title":"Int. J. Cardiol."},{"key":"865_CR112","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10528-017-9839-0","volume":"56","author":"E Teker","year":"2018","unstructured":"Teker, E. et al. Association between the interferon \u03b3 874 T\/A polymorphism and the severity of valvular damage in patients with rheumatic heart disease. Biochem. Genet. 56, 225\u2013234 (2018).","journal-title":"Biochem. Genet."},{"key":"865_CR113","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0002-9440(10)63415-3","volume":"165","author":"L Guilherme","year":"2004","unstructured":"Guilherme, L. et al. Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am. J. Pathol. 165, 1583\u20131591 (2004).","journal-title":"Am. J. Pathol."},{"key":"865_CR114","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41590-017-0023-9","volume":"19","author":"O Rouxel","year":"2018","unstructured":"Rouxel, O. et al. Author Correction: cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat. Immunol. 19, 1035 (2018).","journal-title":"Nat. Immunol."},{"key":"865_CR115","doi-asserted-by":"publisher","first-page":"770275","DOI":"10.3389\/fimmu.2021.770275","volume":"12","author":"E Bianchi","year":"2021","unstructured":"Bianchi, E., Rogge, L. & Vecellio, M. Role of the IL-23\/IL-17 pathway in chronic immune-mediated inflammatory diseases: mechanisms and targeted therapies. Front. Immunol. 12, 770275 (2021).","journal-title":"Front. Immunol."},{"key":"865_CR116","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/jgh.13242","volume":"31","author":"K Haga","year":"2016","unstructured":"Haga, K. et al. MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis. J. Gastroenterol. Hepatol. 31, 965\u2013972 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"865_CR117","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23907\/2018.010","volume":"8","author":"KM Thompson","year":"2018","unstructured":"Thompson, K. M., Sterkel, A. K., McBride, J. A. & Corliss, R. F. The shock of strep: rapid deaths due to Group A Streptococcus. Acad. Forensic Pathol. 8, 136\u2013149 (2018).","journal-title":"Acad. Forensic Pathol."},{"key":"865_CR118","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.3390\/cancers13184647","volume":"13","author":"E Catafal-Tardos","year":"2021","unstructured":"Catafal-Tardos, E., Baglioni, M. V. & Bekiaris, V. Inhibiting the unconventionals: importance of immune checkpoint receptors in \u03b3\u03b4 T, MAIT, and NKT cells. Cancers 13, 4647 (2021).","journal-title":"Cancers"},{"key":"865_CR119","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1161\/CIRCULATIONAHA.118.033891","volume":"138","author":"ML Kim","year":"2018","unstructured":"Kim, M. L. et al. Dysregulated IL-1\u03b2\u2013GM\u2013CSF axis in acute rheumatic fever that is limited by hydroxychloroquine. Circulation 138, 2648\u20132661 (2018).","journal-title":"Circulation"},{"key":"865_CR120","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/scitranslmed.3008706","volume":"6","author":"R Noster","year":"2014","unstructured":"Noster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 80 (2014).","journal-title":"Sci. Transl. Med."},{"key":"865_CR121","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fimmu.2020.00539","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang, J. & Han, B. Dysregulated CD4+ T cells and microRNAs in myocarditis. Front. Immunol. 11, 539 (2020).","journal-title":"Front. Immunol."},{"key":"865_CR122","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85851","volume":"1","author":"JM Myers","year":"2016","unstructured":"Myers, J. M. et al. Cardiac myosin-TH17 responses promote heart failure in human myocarditis. JCI Insight 1, e85851 (2016).","journal-title":"JCI Insight"},{"key":"865_CR123","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10753-013-9606-2","volume":"36","author":"KC Fa\u00e9","year":"2013","unstructured":"Fa\u00e9, K. C. et al. CXCL9\/Mig mediates T cells recruitment to valvular tissue lesions of chronic rheumatic heart disease patients. Inflammation 36, 800\u2013811 (2013).","journal-title":"Inflammation"},{"key":"865_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/srep42179","volume":"7","author":"MB Hansen","year":"2017","unstructured":"Hansen, M. B. et al. Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study. Sci. Rep. 7, 42179 (2017).","journal-title":"Sci. Rep."},{"key":"865_CR125","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.47.1.91","volume":"47","author":"RC Lancefield","year":"1928","unstructured":"Lancefield, R. C. The antigenic complex of Streptococcus haemolyticus: specific substance in extracts of Streptococcus haemolyticus. J. Exp. Med. 47, 91\u2013103 (1928).","journal-title":"J. Exp. Med."},{"key":"865_CR126","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1128\/jcm.34.4.953-958.1996","volume":"34","author":"B Beall","year":"1996","unstructured":"Beall, B., Facklam, R. & Thompson, T. Sequencing emm-specific PCR products for routine and accurate typing of Group A streptococci. J. Clin. Microbiol. 34, 953\u2013958 (1996).","journal-title":"J. Clin. Microbiol."},{"key":"865_CR127","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2958.1994.tb01301.x","volume":"14","author":"AM Whatmore","year":"1994","unstructured":"Whatmore, A. M., Kapur, V., Sullivan, D. J., Musser, J. M. & Kehoe, M. A. Non-congruent relationships between variation in emm gene sequences and the population genetic structure of Group A streptococci. Mol. Microbiol. 14, 619\u2013631 (1994).","journal-title":"Mol. Microbiol."},{"key":"865_CR128","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00315-22","volume":"60","author":"A Fri\u00e3es","year":"2022","unstructured":"Fri\u00e3es, A., Mamede, R., Ferreira, M., Melo-Cristino, J. & Ramirez, M. Annotated whole-genome multilocus sequence typing schema for scalable high-resolution typing of Streptococcus pyogenes. J. Clin. Microbiol. 60, e0031522 (2022).","journal-title":"J. Clin. Microbiol."},{"key":"865_CR129","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.meegid.2020.104609","volume":"86","author":"MG Jespersen","year":"2020","unstructured":"Jespersen, M. G., Lacey, J. A., Tong, S. Y. C. & Davies, M. R. Global genomic epidemiology of Streptococcus pyogenes. Infect. Genet. Evol. 86, 104609 (2020).","journal-title":"Infect. Genet. Evol."},{"key":"865_CR130","doi-asserted-by":"publisher","unstructured":"Bessen, D. E., Smeesters, P. R. & Beall, B. W. Molecular epidemiology, ecology, and evolution of Group A streptococci. Microbiol. Spectr. 6, https:\/\/doi.org\/10.1128\/microbiolspec.CPP3-0009-2018 (2018).","DOI":"10.1128\/microbiolspec.CPP3-0009-2018"},{"key":"865_CR131","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.meegid.2014.10.011","volume":"33","author":"DE Bessen","year":"2015","unstructured":"Bessen, D. E. et al. Molecular epidemiology and genomics of Group A Streptococcus. Infect. Genet. Evol. 33, 393\u2013418 (2015).","journal-title":"Infect. Genet. Evol."},{"key":"865_CR132","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00469-22","volume":"8","author":"SY Bah","year":"2022","unstructured":"Bah, S. Y. et al. Genomic characterization of skin and soft tissue Streptococcus pyogenes isolates from a low-income and a high-income setting. mSphere 8,\u00a0e0046922\u00a0(2022).","journal-title":"mSphere"},{"key":"865_CR133","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3201\/eid2202.151358","volume":"22","author":"AC Seale","year":"2016","unstructured":"Seale, A. C. et al. Invasive Group A Streptococcus infection among children, rural Kenya. Emerg. Infect. Dis. 22, 224\u2013232 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR134","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1017\/S095026881500326X","volume":"144","author":"AC Bowen","year":"2016","unstructured":"Bowen, A. C. et al. Whole genome sequencing reveals extensive community-level transmission of Group A Streptococcus in remote communities. Epidemiol. Infect. 144, 1991\u20131998 (2016).","journal-title":"Epidemiol. Infect."},{"key":"865_CR135","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1473-3099(20)30279-6","volume":"20","author":"Y Li","year":"2020","unstructured":"Li, Y., Nanduri, S. A., Van Beneden, C. A. & Beall, B. W. M1 lineage in invasive Group A Streptococcus isolates from the USA. Lancet Infect. Dis. 20, 538\u2013539 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR136","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1473-3099(20)30278-4","volume":"20","author":"LW R\u00fcmke","year":"2020","unstructured":"R\u00fcmke, L. W. et al. Dominance of M1 clade among dutch M1 Streptococcus pyogenes. Lancet Infect. Dis. 20, 539\u2013540 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR137","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/S1473-3099(19)30622-X","volume":"19","author":"W Demczuk","year":"2019","unstructured":"Demczuk, W., Martin, I., Domingo, F. R., MacDonald, D. & Mulvey, M. R. Identification of Streptococcus pyogenes M1 clone in Canada. Lancet Infect. Dis. 19, 1284\u20131285 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR138","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/infdis\/jiac162","volume":"226","author":"B Metcalf","year":"2022","unstructured":"Metcalf, B. et al. Cluster transmission drives invasive Group A Streptococcus disease within the United States and is focused on communities experiencing disadvantage. J. Infect. Dis. 226, 546\u2013553 (2022).","journal-title":"J. Infect. Dis."},{"key":"865_CR139","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/infdis\/jiab565","volume":"225","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Genomic characterization of Group A streptococci causing pharyngitis and invasive disease in Colorado, USA, June 2016\u2013April 2017. J. Infect. Dis. 225, 1841\u20131851 (2022).","journal-title":"J. Infect. Dis."},{"key":"865_CR140","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3201\/eid2805.211497","volume":"28","author":"LE Nabarro","year":"2022","unstructured":"Nabarro, L. E. et al. Invasive Group A Streptococcus outbreaks associated with home healthcare, England, 2018\u20132019. Emerg. Infect. Dis. 28, 915\u2013923 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"865_CR141","doi-asserted-by":"publisher","first-page":"248.e1","DOI":"10.1016\/j.cmi.2018.04.034","volume":"25","author":"SA Nanduri","year":"2019","unstructured":"Nanduri, S. A. et al. Prolonged and large outbreak of invasive Group A Streptococcus disease within a nursing home: repeated intrafacility transmission of a single strain. Clin. Microbiol. Infect. 25, 248.e1\u2013248.e7 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"865_CR142","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1016\/S2666-5247(21)00332-3","volume":"3","author":"R Cordery","year":"2022","unstructured":"Cordery, R. et al. Frequency of transmission, asymptomatic shedding, and airborne spread of Streptococcus pyogenes in schoolchildren exposed to scarlet fever: a prospective, longitudinal, multicohort, molecular epidemiological, contact-tracing study in England, UK. Lancet Microbe 3, e366\u2013e375 (2022).","journal-title":"Lancet Microbe"},{"key":"865_CR143","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.3390\/ijerph191610215","volume":"19","author":"AP Ralph","year":"2022","unstructured":"Ralph, A. P. et al. Evaluation of a community-led program for primordial and primary prevention of rheumatic fever in remote Northern Australia. Int. J. Environ. Res. Public. Health 19, 10215 (2022).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"865_CR144","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","volume":"21","author":"A Babiker","year":"2021","unstructured":"Babiker, A. et al. Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect. Dis. 21, 697\u2013710 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR145","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(80)91832-2","volume":"2","author":"AS Gastanaduy","year":"1980","unstructured":"Gastanaduy, A. S., Huwe, B. B., Wannamaker, L. W., Kaplan, E. L. & Mckay, C. Failure of penicillin to eradicate Group A streptococci during an outbreak of pharyngitis. Lancet 2, 498\u2013502 (1980).","journal-title":"Lancet"},{"key":"865_CR146","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1542\/peds.108.5.1180","volume":"108","author":"EL Kaplan","year":"2001","unstructured":"Kaplan, E. L. & Johnson, D. R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of Group A streptococci from children with acute pharyngitis. Pediatrics 108, 1180\u20131186 (2001).","journal-title":"Pediatrics"},{"key":"865_CR147","doi-asserted-by":"publisher","first-page":"e4592","DOI":"10.1093\/cid\/ciaa976","volume":"73","author":"DL Horn","year":"2021","unstructured":"Horn, D. L. et al. Outcomes of \u03b2-hemolytic streptococcal necrotizing skin and soft-tissue infections and the impact of clindamycin resistance. Clin. Infect. Dis. 73, e4592\u2013e4598 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR148","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1128\/AAC.42.2.257","volume":"42","author":"H Seppala","year":"1998","unstructured":"Seppala, H., Skurnik, M., Soini, H., Roberts, M. C. & Huovinen, P. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob. Agents Chemother. 42, 257\u2013262 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR149","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fmicb.2015.00026","volume":"6","author":"ST Chancey","year":"2015","unstructured":"Chancey, S. T. et al. Composite mobile genetic elements disseminating macrolide resistance in Streptococcus pneumoniae. Front. Microbiol. 6, 26 (2015).","journal-title":"Front. Microbiol."},{"key":"865_CR150","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3389\/fmicb.2020.00797","volume":"11","author":"O Oppegaard","year":"2020","unstructured":"Oppegaard, O., Skrede, S., Mylvaganam, H. & Kittang, B. R. Emerging threat of antimicrobial resistance in \u03b2-hemolytic streptococci. Front. Microbiol. 11, 797 (2020).","journal-title":"Front. Microbiol."},{"key":"865_CR151","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1128\/AAC.01352-07","volume":"52","author":"RL Woodbury","year":"2008","unstructured":"Woodbury, R. L. et al. Plasmid-borne erm(T) from invasive, macrolide-resistant Streptococcus pyogenes strains. Antimicrob. Agents Chemother. 52, 1140\u20131143 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR152","doi-asserted-by":"publisher","first-page":"e1266","DOI":"10.1093\/cid\/ciac468","volume":"76","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Continued increase of erythromycin\u00a0nonsusceptibility and clindamycin nonsusceptibility among invasive Group A streptococci driven by genomic clusters, USA, 2018\u20132019. Clin. Infect. Dis. 76,\u00a0e1266\u2013e1269 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR153","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1128\/AAC.01877-13","volume":"58","author":"JS Lewis","year":"2014","unstructured":"Lewis, J. S. et al. Failure of clindamycin to eradicate infection with \u03b2-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections. Antimicrob. Agents Chemother. 58, 1327\u20131331 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR154","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/S1473-3099(21)00699-X","volume":"21","author":"DL Yu","year":"2021","unstructured":"Yu, D. L., Liang, Y. M., Zheng, Y. J. & Yang, Y. H. Clindamycin-resistant Streptococcus pyogenes in Chinese children. Lancet Infect. Dis. 21, 1631\u20131632 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"865_CR155","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-2958.1996.01521.x","volume":"22","author":"J Clancy","year":"1996","unstructured":"Clancy, J. et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol. Microbiol. 22, 867\u2013879 (1996).","journal-title":"Mol. Microbiol."},{"key":"865_CR156","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs). CDC https:\/\/www.cdc.gov\/abcs\/reports-findings\/surv-reports.html (2019)."},{"key":"865_CR157","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/cid\/ciab575","volume":"73","author":"K Fay","year":"2021","unstructured":"Fay, K. et al. Patterns of antibiotic nonsusceptibility among invasive Group A Streptococcus infections \u2014 United States, 2006\u20132017. Clin. Infect. Dis. 73, 1957\u20131964 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR158","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/cid\/ciaa027","volume":"72","author":"T Bruun","year":"2021","unstructured":"Bruun, T. et al. Risk factors and predictors of mortality in streptococcal necrotizing soft-tissue infections: a multicenter prospective study. Clin. Infect. Dis. 72, 293\u2013300 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR159","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/j.1469-0691.2008.02104.x","volume":"14","author":"C Silva-Costa","year":"2008","unstructured":"Silva-Costa, C., Pinto, F. R., Ramirez, M. & Melo-Cristino, J., Portuguese Surveillance Group for the Study of Respiratory Pathogens. Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal. Clin. Microbiol. Infect. 14, 1152\u20131159 (2008).","journal-title":"Clin. Microbiol. Infect."},{"key":"865_CR160","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1128\/AAC.01054-06","volume":"51","author":"E Perez-Trallero","year":"2007","unstructured":"Perez-Trallero, E. et al. Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob. Agents Chemother. 51, 1228\u20131233 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR161","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S0924-8579(03)00062-1","volume":"21","author":"I Rodriguez-Avial","year":"2003","unstructured":"Rodriguez-Avial, I., Rodriguez-Avial, C., Culebras, E. & Picazo, J. J. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans Group streptococci harbouring erm(B) and mef(A) genes. Susceptibility to quinupristin\/dalfopristin and linezolid. Int. J. Antimicrob. Agents 21, 536\u2013541 (2003).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"865_CR162","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jmii.2020.08.019","volume":"54","author":"WC Tsai","year":"2021","unstructured":"Tsai, W. C. et al. Emergence of macrolide-resistant Streptococcus pyogenes emm12 in southern Taiwan from 2000 to 2019. J. Microbiol. Immunol. Infect. 54, 1086\u20131093 (2021).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"865_CR163","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1099\/jmm.0.2008\/002642-0","volume":"57","author":"T Wajima","year":"2008","unstructured":"Wajima, T. et al. Distribution of emm type and antibiotic susceptibility of Group A streptococci causing invasive and noninvasive disease. J. Med. Microbiol. 57, 1383\u20131388 (2008).","journal-title":"J. Med. Microbiol."},{"key":"865_CR164","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jiac.2019.10.004","volume":"26","author":"K Tatara","year":"2020","unstructured":"Tatara, K. et al. Molecular epidemiology, antimicrobial susceptibility, and characterization of fluoroquinolone non-susceptible Streptococcus pyogenes in Japan. J. Infect. Chemother. 26, 280\u2013284 (2020).","journal-title":"J. Infect. Chemother."},{"key":"865_CR165","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1099\/jmm.0.001158","volume":"69","author":"K Ubukata","year":"2020","unstructured":"Ubukata, K. et al. Changes in epidemiologic characteristics and antimicrobial resistance of Streptococcus pyogenes isolated over 10\u2009years from Japanese children with pharyngotonsillitis. J. Med. Microbiol. 69, 443\u2013450 (2020).","journal-title":"J. Med. Microbiol."},{"key":"865_CR166","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fmicb.2018.00542","volume":"9","author":"YF Shen","year":"2018","unstructured":"Shen, Y. F. et al. Identification and characterization of fluoroquinolone non-susceptible Streptococcus pyogenes clones harboring tetracycline and macrolide resistance in Shanghai, China. Front. Microbiol. 9, 542 (2018).","journal-title":"Front. Microbiol."},{"key":"865_CR167","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/S2542-5196(21)00280-1","volume":"5","author":"AJ Browne","year":"2021","unstructured":"Browne, A. J. et al. Global antibiotic consumption and usage in humans, 2000\u201318: a spatial modelling study. Lancet Planet. Health 5, e893\u2013e904 (2021).","journal-title":"Lancet Planet. Health"},{"key":"865_CR168","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.clinthera.2021.04.013","volume":"43","author":"G Gahlawat","year":"2021","unstructured":"Gahlawat, G. et al. Emerging treatment strategies for impetigo in endemic and nonendemic settings: a systematic review. Clin. Ther. 43, 986\u20131006 (2021).","journal-title":"Clin. Ther."},{"key":"865_CR169","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/320532","volume":"32","author":"P Huovinen","year":"2001","unstructured":"Huovinen, P. Resistance to trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 32, 1608\u20131614 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR170","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1128\/AAC.01284-12","volume":"56","author":"R Bergmann","year":"2012","unstructured":"Bergmann, R., Sagar, V., Nitsche-Schmitz, D. P. & Chhatwal, G. D. First detection of trimethoprim resistance determinant dfrG in Streptococcus pyogenes clinical isolates in India. Antimicrob. Agents Chemother. 56, 5424\u20135425 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34243-3","volume":"13","author":"MKD Rodrigo","year":"2022","unstructured":"Rodrigo, M. K. D. et al. Host-dependent resistance of Group A Streptococcus to sulfamethoxazole mediated by a horizontally-acquired reduced folate transporter. Nat. Commun. 13, 6557 (2022). This study uses a combination of in vitro evolution and metabolic rescue experiments to demonstrate that a new antimicrobial resistance mechanism \u2014 undetectable using traditional laboratory testing methods \u2014 is responsible for high levels of resistance to sulfamethoxazole in GAS.","journal-title":"Nat. Commun."},{"key":"865_CR172","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1128\/AAC.22.1.128","volume":"22","author":"L Gutmann","year":"1982","unstructured":"Gutmann, L. & Tomasz, A. Penicillin-resistant and penicillin-tolerant mutants of Group A streptococci. Antimicrob. Agents Chemother. 22, 128\u2013136 (1982).","journal-title":"Antimicrob. Agents Chemother."},{"key":"865_CR173","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.ajpath.2020.04.014","volume":"190","author":"RJ Olsen","year":"2020","unstructured":"Olsen, R. J., Zhu, L. C. & Musser, J. M. A single amino acid replacement in penicillin-binding protein 2X in Streptococcus pyogenes significantly increases fitness on subtherapeutic benzylpenicillin treatment in a mouse model of necrotizing myositis. Am. J. Pathol. 190, 1625\u20131631 (2020).","journal-title":"Am. J. Pathol."},{"key":"865_CR174","first-page":"72197","volume":"70","author":"Food and Drug Administration, HHS.","year":"2005","unstructured":"Food and Drug Administration, HHS. Revocation of status of specific products; Group A Streptococcus. Direct final rule. Fed. Regist. 70, 72197\u201372199 (2005).","journal-title":"Fed. Regist."},{"key":"865_CR175","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","volume":"38","author":"\u00c9 Pastural","year":"2020","unstructured":"Pastural, \u00c9. et al. Safety and immunogenicity of a 30-valent M protein-based Group A streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine 38, 1384\u20131392 (2020).","journal-title":"Vaccine"},{"key":"865_CR176","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","volume":"29","author":"JB Dale","year":"2011","unstructured":"Dale, J. B., Penfound, T. A., Chiang, E. Y. & Walton, W. J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of Group A streptococci. Vaccine 29, 8175\u20138178 (2011).","journal-title":"Vaccine"},{"key":"865_CR177","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/infdis\/jiu260","volume":"210","author":"M Sanderson-Smith","year":"2014","unstructured":"Sanderson-Smith, M. et al. A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J. Infect. Dis. 210, 1325\u20131338 (2014).","journal-title":"J. Infect. Dis."},{"key":"865_CR178","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.vaccine.2013.01.019","volume":"31","author":"JB Dale","year":"2013","unstructured":"Dale, J. B. et al. Potential coverage of a multivalent M protein-based Group A streptococcal vaccine. Vaccine 31, 1576\u20131581 (2013).","journal-title":"Vaccine"},{"key":"865_CR179","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/INF.0b013e3182a5c32a","volume":"33","author":"ME Engel","year":"2014","unstructured":"Engel, M. E. et al. Group A streptococcal emm type prevalence among symptomatic children in Cape Town and potential vaccine coverage. Pediatr. Infect. Dis. J. 33, 208\u2013210 (2014).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"865_CR180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007511","volume":"13","author":"PM Giffard","year":"2019","unstructured":"Giffard, P. M., Tong, S. Y. C., Holt, D. C., Ralph, A. P. & Currie, B. J. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease. PLoS Negl. Trop. Dis. 13, e0007511 (2019).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"865_CR181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198658","volume":"13","author":"S Sekuloski","year":"2018","unstructured":"Sekuloski, S. et al. Evaluation of safety and immunogenicity of a Group A Streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE 13, e0198658 (2018).","journal-title":"PLoS ONE"},{"key":"865_CR182","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.4049\/jimmunol.1501994","volume":"196","author":"M Pandey","year":"2016","unstructured":"Pandey, M. et al. Combinatorial synthetic peptide vaccine strategy protects against hypervirulent CovR\/S mutant streptococci. J. Immunol. 196, 3364\u20133374 (2016).","journal-title":"J. Immunol."},{"key":"865_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060969","volume":"8","author":"E Postol","year":"2013","unstructured":"Postol, E. et al. StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. PLoS ONE 8, e60969 (2013).","journal-title":"PLoS ONE"},{"key":"865_CR184","doi-asserted-by":"publisher","first-page":"e03537-20","DOI":"10.1128\/mBio.03537-20","volume":"12","author":"V Ozberk","year":"2021","unstructured":"Ozberk, V. et al. Prime-pull immunization with a bivalent M-protein and Spy-CEP peptide vaccine adjuvanted with CAF\u00ae01 liposomes induces both mucosal and peripheral protection from covR\/S mutant Streptococcus pyogenes. mBio 12, e03537-20 (2021).","journal-title":"mBio"},{"key":"865_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80508-6","volume":"11","author":"S Reynolds","year":"2021","unstructured":"Reynolds, S. et al. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines. Sci. Rep. 11, 127 (2021).","journal-title":"Sci. Rep."},{"key":"865_CR186","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46244-2","volume":"9","author":"E Postol","year":"2019","unstructured":"Postol, E. et al. Group A Streptococcus adsorbed vaccine: repeated intramuscular dose toxicity test in minipigs. Sci. Rep. 9, 9733 (2019).","journal-title":"Sci. Rep."},{"key":"865_CR187","doi-asserted-by":"publisher","first-page":"M111.015693","DOI":"10.1074\/mcp.M111.015693","volume":"11","author":"G Bensi","year":"2012","unstructured":"Bensi, G. et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol. Cell. Proteom. 11, M111.015693 (2012).","journal-title":"Mol. Cell. Proteom."},{"key":"865_CR188","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IM9.0000000000000044","volume":"3","author":"NJ Gao","year":"2021","unstructured":"Gao, N. J. et al. Site-specific conjugation of cell wall polyrhamnose to protein SpyAD envisioning a safe universal Group A streptococcal vaccine. Infect. Microbes Dis. 3, 87 (2021).","journal-title":"Infect. Microbes Dis."},{"key":"865_CR189","doi-asserted-by":"publisher","first-page":"e00618-16","DOI":"10.1128\/mBio.00618-16","volume":"7","author":"T Rivera-Hernandez","year":"2016","unstructured":"Rivera-Hernandez, T. et al. Differing efficacies of lead Group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models. mBio 7, e00618-16 (2016).","journal-title":"mBio"},{"key":"865_CR190","doi-asserted-by":"publisher","first-page":"e00122-20","DOI":"10.1128\/mBio.00122-20","volume":"11","author":"T Rivera-Hernandez","year":"2020","unstructured":"Rivera-Hernandez, T. et al. Vaccine-induced TH1-type response protects against invasive Group A Streptococcus infection in the absence of opsonizing antibodies. mBio 11, e00122-20 (2020).","journal-title":"mBio"},{"key":"865_CR191","doi-asserted-by":"publisher","first-page":"e02600","DOI":"10.1128\/mBio.02600-19","volume":"10","author":"S Bi","year":"2019","unstructured":"Bi, S. et al. A multicomponent vaccine provides immunity against local and systemic infections by Group A Streptococcus across serotypes. mBio 10, e02600\u2013e02619 (2019).","journal-title":"mBio"},{"key":"865_CR192","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jinf.2016.02.002","volume":"72","author":"M Reglinski","year":"2016","unstructured":"Reglinski, M., Lynskey, N. N., Choi, Y. J., Edwards, R. J. & Sriskandan, S. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG. J. Infect. 72, 450\u2013459 (2016).","journal-title":"J. Infect."},{"key":"865_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83673-4","volume":"11","author":"JMS Loh","year":"2021","unstructured":"Loh, J. M. S. et al. A multivalent T-antigen-based vaccine for Group A Streptococcus. Sci. Rep. 11, 4353 (2021).","journal-title":"Sci. Rep."},{"key":"865_CR194","unstructured":"World Health Organization. Rheumatic fever and rheumatic heart disease. Report by the Director General. Seventy-First World Health Assembly (WHO, 2018)."},{"key":"865_CR195","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/cid\/ciab597","volume":"74","author":"K Andrejko","year":"2022","unstructured":"Andrejko, K., Whittles, L. K. & Lewnard, J. A. Health-economic value of vaccination against Group A Streptococcus in the United States. Clin. Infect. Dis. 74, 983\u2013992 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00222-2","volume":"5","author":"J-LS Mills","year":"2020","unstructured":"Mills, J.-L. S. et al. M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP). NPJ Vaccines 5, 74 (2020).","journal-title":"NPJ Vaccines"},{"key":"865_CR197","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-0716-0467-0_24","volume":"2136","author":"T Rivera-Hernandez","year":"2020","unstructured":"Rivera-Hernandez, T. & Walker, M. J. Humanized plasminogen mouse model to study Group A Streptococcus invasive disease. Methods Mol. Biol. 2136, 309\u2013316 (2020).","journal-title":"Methods Mol. Biol."},{"key":"865_CR198","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-0716-0467-0_22","volume":"2136","author":"M Pandey","year":"2020","unstructured":"Pandey, M. & Good, M. F. A superficial skin scarification method in mice to mimic Streptococcus pyogenes skin infection in humans. Methods Mol. Biol. 2136, 287\u2013301 (2020).","journal-title":"Methods Mol. Biol."},{"key":"865_CR199","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10096-019-03719-4","volume":"39","author":"P Konrad","year":"2020","unstructured":"Konrad, P., Hufnagel, M., Berner, R. & Toepfner, N. Long-term, single-center surveillance of non-invasive Group A streptococcal (GAS) infections, emm types and emm clusters. Eur. J. Clin. Microbiol. Infect. Dis. 39, 273\u2013280 (2020).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"865_CR200","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-0484","volume":"121","author":"E Pfoh","year":"2008","unstructured":"Pfoh, E., Wessels, M. R., Goldmann, D. & Lee, G. M. Burden and economic cost of Group A streptococcal pharyngitis. Pediatrics 121, 229\u2013234 (2008).","journal-title":"Pediatrics"},{"key":"865_CR201","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4161\/viru.2.5.16342","volume":"2","author":"D Metzgar","year":"2011","unstructured":"Metzgar, D. & Zampolli, A. The M protein of Group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence 2, 402\u2013412 (2011).","journal-title":"Virulence"},{"key":"865_CR202","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of Group A streptococcal diseases. Lancet Infect. Dis. 5, 685\u2013694 (2005). This paper is a comprehensive epidemiological analysis of the global health burden of GAS diseases.","journal-title":"Lancet Infect. Dis."},{"key":"865_CR203","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1136\/hrt.2007.141309","volume":"94","author":"KB Tibazarwa","year":"2008","unstructured":"Tibazarwa, K. B., Volmink, J. A. & Mayosi, B. M. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart 94, 1534\u20131540 (2008).","journal-title":"Heart"},{"key":"865_CR204","doi-asserted-by":"crossref","unstructured":"Watkins, D., Baker, M. G., Kumar, R. K. & Parks, T. in Acute Rheumatic Fever and Rheumatic Heart Disease Ch. 1 (eds Dougherty, S., Carapetis, J., Z\u00fchlke, L. & Wilson, N.) 1\u201318 (Elsevier, 2021).","DOI":"10.1016\/B978-0-323-63982-8.00001-5"},{"key":"865_CR205","unstructured":"Institute for Health Metrics and Evaluation, University of Washington. GBD results. IHME http:\/\/vizhub.healthdata.org\/gbd-results (2022)."},{"key":"865_CR206","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41581-019-0178-8","volume":"16","author":"AA Satoskar","year":"2020","unstructured":"Satoskar, A. A., Parikh, S. V. & Nadasdy, T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis. Nat. Rev. Nephrol. 16, 32\u201350 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"865_CR207","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/bmb\/ldv027","volume":"115","author":"T Parks","year":"2015","unstructured":"Parks, T., Barrett, L. & Jones, N. Invasive streptococcal disease: a review for clinicians. Br. Med. Bull. 115, 77\u201389 (2015).","journal-title":"Br. Med. Bull."},{"key":"865_CR208","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10096-011-1385-9","volume":"31","author":"S Rantala","year":"2012","unstructured":"Rantala, S. et al. Streptococcus pyogenes bacteraemia, emm types and superantigen profiles. Eur. J. Clin. Microbiol. Infect. Dis. 31, 859\u2013865 (2012).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"865_CR209","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54409-2","volume":"9","author":"A Fri\u00e3es","year":"2019","unstructured":"Fri\u00e3es, A., Melo-Cristino, J. & Ramirez, M., & Portuguese Group for the Study of Streptococcal Infections. Changes in emm types and superantigen gene content of Streptococcus pyogenes causing invasive infections in Portugal. Sci. Rep. 9, 18051 (2019).","journal-title":"Sci. Rep."},{"key":"865_CR210","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/jama.2016.8825","volume":"316","author":"AB Raff","year":"2016","unstructured":"Raff, A. B. & Kroshinsky, D. Cellulitis: a review. JAMA 316, 325\u2013337 (2016).","journal-title":"JAMA"},{"key":"865_CR211","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4997\/JRCPE.2011.411","volume":"41","author":"S Sriskandan","year":"2011","unstructured":"Sriskandan, S. Severe peripartum sepsis. J. R. Coll. Physicians Edinb. 41, 339\u2013346 (2011).","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"865_CR212","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/cid\/cit282","volume":"57","author":"SM Hamilton","year":"2013","unstructured":"Hamilton, S. M., Stevens, D. L. & Bryant, A. E. Pregnancy-related group a streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin. Infect. Dis. 57, 870\u2013876 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR213","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/cid\/ciy401","volume":"67","author":"T Parks","year":"2018","unstructured":"Parks, T., Wilson, C., Curtis, N., Norrby-Teglund, A. & Sriskandan, S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin. Infect. Dis. 67, 1434\u20131436 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR214","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jama.292.6.709","volume":"292","author":"KL Kotloff","year":"2004","unstructured":"Kotloff, K. L. et al. Safety and immunogenicity of a recombinant multivalent Group A streptococcal vaccine in healthy adults: phase 1 trial. JAMA 292, 709\u2013715 (2004).","journal-title":"JAMA"},{"key":"865_CR215","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1086\/444458","volume":"41","author":"SA McNeil","year":"2005","unstructured":"McNeil, S. A. et al. Safety and immunogenicity of 26-valent Group A Streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114\u20131122 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"865_CR216","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ics.2005.12.002","volume":"1289","author":"SA McNeil","year":"2006","unstructured":"McNeil, S. A. et al. A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent Group A streptococcus vaccine in healthy adults. Int. Congr. Ser. 1289, 303\u2013306 (2006).","journal-title":"Int. Congr. Ser."}],"updated-by":[{"DOI":"10.1038\/s41579-023-00939-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000}}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00865-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00865-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00865-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:35:20Z","timestamp":1733938520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-023-00865-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":216,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1038\/s41579-023-00865-7","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"6 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41579-023-00939-6","URL":"https:\/\/doi.org\/10.1038\/s41579-023-00939-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}